Hildenbrand Ralf, Schaaf Antonela
Institut für Pathologie, 53123 Bonn, Germany.
Int J Oncol. 2009 Jan;34(1):15-23.
The urokinase-system has been implicated in tumor spread. The serine protease urokinase-type plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1) are involved in the control of extracellular turnover, cell migration, invasion, cell signalling, proliferation, apoptosis and angiogenesis leading to a variety of different responses, under both physiological and pathological conditions. uPA and PAI-1 were the first novel tumor biological factors to be validated at the highest level of evidence regarding their clinical utility in breast cancer. However, it is unclear whether it is their (relative) levels in the tumor stroma or in the tumor cells themselves that is the most relevant to patients outcome. This is the first study in which tumor cells and stromal tissue of invasive breast carcinomas were separated by laser capture microdissection followed by ELISA-based determination of the uPA, uPAR and PAI-1 levels. In addition, we localized uPA, uPAR and PAI-1 distribution in invasive breast cancer (n=30) and in ductal carcinoma in situ (DCIS, n=30) by immunohistochemistry and in situ hybridization. We have demonstrated that no significant differences between uPA, uPAR and PAI-1 levels in tumor stroma only, tumor cells only and not separated breast cancer tissue exist (p>0.05). Our results suggest that similar expression levels of these factors in both compartments and in not separated breast cancer tissue may have the same impact on the clinical behavior of breast cancer. These results are an important issue for practical use of tissue sampling. For using uPA and PAI-1 levels as prognostic and predictive factors in breast cancer the quantity of tumor stroma in the tumor tissue specimen is not relevant for assessment patients outcome. Our results were confirmed by immunohistochemistry and in situ hybridization analysis showing that in nearly all cases of invasive carcinomas and DCIS fibroblasts as well as macrophages strongly express uPA, uPAR and PAI-1. Prompted by our immunohistological results that nearly all myoepithelial cells of DCIS exhibit uPA, uPAR and PAI-1, we investigated these important host cells in detail. We have demonstrated by multimodal methods that uPAR and PAI-1 protein and mRNA is expressed in most myoepithelial cells of DCIS. Additionally, we furnish evidence that uPAR expression of myoepithelial cells are important for uPAR Vitronectin-associated cell-matrix interaction, which regulates cell adhesion and detachment. We speculate that the loss of the anti-invasive myoepithelial cell layer in DCIS may be triggered by PAI-1 and could be an early sign of subsequent tumor cell invasion.
尿激酶系统与肿瘤扩散有关。丝氨酸蛋白酶尿激酶型纤溶酶原激活剂(uPA)、其受体(uPAR)及其抑制剂(PAI-1)参与细胞外周转、细胞迁移、侵袭、细胞信号传导、增殖、凋亡和血管生成的调控,在生理和病理条件下会导致多种不同反应。uPA和PAI-1是首批在乳腺癌临床应用方面获得最高证据水平验证的新型肿瘤生物学因子。然而,尚不清楚在肿瘤基质中还是肿瘤细胞本身的(相对)水平与患者预后最为相关。这是第一项通过激光捕获显微切割分离浸润性乳腺癌的肿瘤细胞和基质组织,随后基于酶联免疫吸附测定法测定uPA、uPAR和PAI-1水平的研究。此外,我们通过免疫组织化学和原位杂交对30例浸润性乳腺癌和30例导管原位癌(DCIS)中的uPA、uPAR和PAI-1分布进行了定位。我们已经证明,仅肿瘤基质、仅肿瘤细胞以及未分离的乳腺癌组织中uPA、uPAR和PAI-1水平之间不存在显著差异(p>0.05)。我们的结果表明,这些因子在两个区室以及未分离的乳腺癌组织中的相似表达水平可能对乳腺癌的临床行为具有相同影响。这些结果对于组织采样的实际应用而言是一个重要问题。对于将uPA和PAI-1水平用作乳腺癌的预后和预测因子,肿瘤组织标本中肿瘤基质的数量与评估患者预后无关。我们的结果通过免疫组织化学和原位杂交分析得到证实,结果显示在几乎所有浸润性癌和DCIS病例中,成纤维细胞以及巨噬细胞均强烈表达uPA、uPAR和PAI-1。基于我们的免疫组织学结果,即几乎所有DCIS的肌上皮细胞均表现出uPA、uPAR和PAI-1,我们对这些重要的宿主细胞进行了详细研究。我们通过多模态方法证明,uPAR和PAI-1蛋白及mRNA在大多数DCIS的肌上皮细胞中表达。此外,我们提供证据表明,肌上皮细胞的uPAR表达对于uPAR与玻连蛋白相关的细胞-基质相互作用很重要,这种相互作用调节细胞黏附和脱离。我们推测,DCIS中抗侵袭性肌上皮细胞层的丧失可能由PAI-1触发,并且可能是随后肿瘤细胞侵袭的早期迹象。